卡培他滨联合顺铂化疗同步放疗对食管癌临床疗效的研究-现代医学

卡培他滨联合顺铂化疗同步放疗对食管癌临床疗效的研究

单位：1. 盐城市第一人民医院心胸外科, 江苏盐城 224000;
2. 盐城市第一人民医院肿瘤科, 江苏盐城 224000

分类号：R735.2

出版年·卷·期（页码）：2019·47·第七期（831-835）

摘要：

目的：评价卡培他滨联合顺铂（DDP）化疗同步放疗用于食管鳞状细胞癌（简称鳞癌）治疗的可行性。方法：以18例食管鳞癌患者为研究对象，化疗方案如下：DDP 60 mg·m^-2，静脉滴注，第1天；卡培他滨825 mg·m^-2，口服，每天2次，第1~14天；每3周为1个周期，重复两周期。针对原发灶及区域淋巴结行放疗，总量60 Gy，每天分割剂量2 Gy，从化疗第1天开始，每周5 d。同步放化疗结束后，继续每3周予卡培他滨1次（1 000 mg·m^-2，每天2次，第1~14天，休息7 d），联合DDP（60 mg·m^-2，第1天），一共2个周期。结果：18例患者均完成了放化疗计划。治疗后11例（61.1%）完全缓解，7例（38.9%）部分缓解。1例患者出现Ⅲ~Ⅳ度中性粒细胞减少，无治疗相关性死亡发生。中位随访时间为13.8个月，两年的总生存率和无进展生存率分别为70.5%和54.0%。结论：卡培他滨联合DDP化疗同步放疗治疗食管鳞癌是患者可以耐受且有效的治疗方案。

Objective:To evaluate the feasibility of concurrent chemoradiotherapy (CRT) with capecitabine and cisplatin in patients with squamous cell esophageal cancer. Methods:Eighteen patients with esophageal squamous cell carcinoma were enrolled in this study. The chemotherapy was consisted of two cycles of intravenous cisplatin of 60 mg·m^-2 at day 1 and oral capecitabine 825 mg·m^-2 twicea day from day 1 to 14 at 3-week intervals. The radiotherapy (2.0 Gy fraction a day to a total dose of 60 Gy) was delivered to the primary tumor site and regional lymph node. After the chemoradiotherapy, two cycles of capecitabine(1 000 mg·m^-2,tice a day from day 1 to 14) plus cisplatin (60 mg·m^-2on day 1) were added every 3 weeks. Results:All the patients had completed the planned treatment. After the CRT, 11 cases were complete responses(61.1%) and 7 cases were partial responses(38.9%). Grade Ⅲ to Ⅳneutropenia only occurred in 1 patients, no treatment-related death was observed. Median follow-up duration was 13.8 months and the estimated overall survival and progression-free survival rate at 2-year was 70.5% and 54.0%, respectively. Conclusion:Concurrent CRT with capecitabine and cisplatin is well-tolerated and effective in patients with squamous cell esophageal cancer.

参考文献：

[1] KATO H,NAKAJIMA M.Treatments for esophageal cancer:a review[J].Gen Thorac Cardiovasc Surg,2013,61(6):330-335.
[2] LORDICK F,HOLSCHER A H,HAUSTERMANS K,et al.Multimodal treatment of esophageal cancer[J].Langenbecks Arch Surg,2013,398(2):177-187.
[3] HAISLEY K R,HART K D,NABAVIZADEH N,et al.Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer[J].Dis Esophagus,2017,30(7):1-7.
[4] ZHU Z Q,ZHU Z A,CAI H X.Continuous infusion of a large dose of CF(folinic acid) and 5-FU combined with CDDP in the treatment of advanced esophageal cancer[J].Int J Clin Pharmacol Ther,2017,55(5):397-402.
[5] HAMAGUCHI T,SHIMADA Y,MIZUSAWA J,et al.Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage Ⅲ colorectal cancer(JCOG0910):an open-label non-inferiority randomized phase 3 multicentre trial[J].Lancet Gastroenterol Hepatol,2018,3(1):47-56.
[6] ELAMIN Y Y,RAFEE S,OSMAN N,et al.Thymidine phosphorylase in cancer:enemy or friend[J].Cancer Microenviron,2016,9(1):33-43.
[7] KOBUCHI S,YAZAKI Y,ITO Y,et al.Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats[J].Eur J Pharm Sci,2018,112:152-158.
[8] TOI M,MASUDA N,LEE S J.Capecitabine for primary breast cancer[J].Oncotarget,2017,8(67):110739-110740.
[9] KU G Y.Systemic therapy for esophageal cancer:chemotherapy[J].Chin Clin Oncol,2017,6(5):49.
[10] WAGNER A D,SYN N L,MOEHLER M,et al.Chemotherapy for advanced gastric cancer[J].Cochrane Database Syst Rev,2017,8:CD004064.
[11] SCHWARTZ L H,LITIÈRE S,DE VRIES E,et al.RECIST 1.1-Update and clarification:From the RECIST committee[J].Eur J Cancer,2016,62:132-137.
[12] FULTON B A,GRAY J,MCDONALD A,et al.Single centre outcomes from definitive chemo-radiotherapy and single modality radiotherapy for lacally advanced oesophageal cancer[J].J Gastrointest Oncol,2016,7(2):166-172.
[13] NAKAJIMA Y,KAWADA K,TOKAIRIN Y,et al.Salvage chemoradiotherapy for locally advanced esophageal carcinomas[J].Dis Esophagus,2015,28(5):460-467.
[14] KUMABE A,ZENDA S,MOTEGI A,et al.Long-term clinical results of concurrent chemoradiotherapy for patients with cervical esophageal squamous cell carcinoma[J].Anticancer Res,2017,37(9):5039-5044.
[15] MOFID B,RAZZAGHDOUST A,KASHI A S,et al.A comparative study of cisplatin-based definitive chemo-radiation in non-metastatic squamous cell carcinoma of the esophagus[J].Electron Physician,2016,8(10):3069-3075.
[16] KWSKMAN J J,PUNT C J.Oral drugs in the treatment of metastatic colorectal cancer[J].Expert Opin Pharmacother,2016,17(10):1351-1361.
[17] GUO Y,XIONG B H,ZHANG T,et al.XELOX vs. FOLFOX in metastatic colorectal cancer:An updated meta-analysis[J].Cancer Invest,2016,34(2):94-104.
[18] IQBAL H,PAN Q.Capecitabine for treating head and neck cancer[J].Expert Opin Investig Drugs,2016,25(7):851-859.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录